Sarepta is a cutting-edge biotechnology company specializing in RNA-targeted therapies, primarily for rare neuromuscular diseases like Duchenne muscular dystrophy (DMD). It develops exon-skipping drugs to restore dystrophin production. Patients with DMD mutations, their families, and healthcare providers benefit most, as treatments aim to slow disease progression and improve quality of life.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends